$ALLR: Great news with potential short squeeze 🚀

$ALLR : Allarity Therapeutics (NASDAQ: ALLR) has announced a $5 million share repurchase program authorized by its Board of Directors, running through February 28, 2026. The company, currently in Phase 2 clinical trials, is developing stenoparib—a dual PARP/Wnt pathway inhibitor—for personalized cancer treatment using its Drug Response Predictor (DRP®) technology.

Increased Short Interest :

Allarity Therapeutics (ALLR) has a short interest of 635,600 shares, representing 18.75% of the float (the number of shares available for trading by the public). This marks a 29.95% increase in short interest from the previous month. The short interest ratio (days to cover) is 0.3, indicating that it would take 0.3 days of the average trading volume of 751,311 shares to cover all short positions.

We see some action and volume after hours, if the volume keeps increasing it may squeeze to $2 and $3 easily.